Challenge with hepatitis B vaccine in children previously vaccinated with a hepatitis B-containing combination vaccine

Advances in Therapy

Volumn 27, Issue 1, 2010, Pages 28-38

  Reinert, Philippe ^a   Cinquetti, Sandro ^b   Soubeyrand, Benoit ^c   Biasio, Luigi R ^d   Meghlaoui, Gilles ^c   Thomas, Stéphane ^c   Watson, Michael ^c  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b Dipartimento di Prevenzione Azienda ULSS 7   (Italy)

^c SANOFI PASTEUR   (France)

^d Sanofi Pasteur MSD   (Italy)

Author keywords

Anamnestic response; Children; Combination vaccine; Hepatitis B vaccine; Immune response

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPTHERIA HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; PRIMAVAX; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY DETECTION; ARTICLE; CHILD; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DOSE RESPONSE; DRUG SAFETY; ENDEMIC DISEASE; FEMALE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOPROPHYLAXIS; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; NONHUMAN; PERTUSSIS; POLIOMYELITIS; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SECONDARY IMMUNE RESPONSE; SINGLE DRUG DOSE; TETANUS; VACCINATION;

CHILD; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MALE; VACCINES, COMBINED;

EID: 77950689511     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0005-x     Document Type: Article

References (33)

1. World Health Organization. Fact Sheet no. 204. Hepatitis B. Revised August 2008. Available at: www.who.int/mediacentre/factsheets/fs204/en/.Accessed October 21, 2009.
2. Anonymous. Hepatitis B vaccines. Wkly Epidemiol Rec. 2004;79:255-263.
3. Grosheide P, Van Damme P. Prevention and control of hepatitis B in the community. In: Hallauer J, Kane M, McCoy E, Meleus A, Moure C (eds), Communicable Diseases Series 1. Copenhagen and Antwerp: WHO & Viral Hepatitis Prevention Board, 1996:1-60.
4. Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr. 1995;126: 716-721.
5. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-Results of a 10-year study. J Infect Dis. 1997;175:674-677.
6. Chadha MS, Arankalle VA. Ten-year serological follow up of hepatitis B vaccine recipients. Indian J Gastroenterol. 2000;19:168-171.
7. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001;20:63-75.
8. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 2000;355:561-565.
9. Fitzsimons D, Francois G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005;23:4158-4166.
10. Banatvala JE, van Damme P. Hepatitis B vaccine-do we need boosters? J Viral Hepat. 2003;10:1-6.
11. West DJ, Watson B, Lichtman J, Hesley TM, Hedberg K. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Pediatr Infect Dis J. 1994;13: 745-747.
12. Liu HB, Meng ZD, Ma JC, et al. A 12-year cohort study on the efficacy of plasma-derived hepatitis B vaccine in rural newborns. World J Gastroenterol. 2000;6:381-383.
13. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine; report of the Centers for Disease Control multi-centre efficacy trial among homosexual men. Ann Intern Med. 1982;97:362-366.
14. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 1996;14:1019-1027.
15. Lieming D, Mintai Z, Yinfu W. A 9-year followup study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis. 1993;17:475-479.
16. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200:1390-1396.
17. van der Sande MAB, Waight PA, Mendy M, et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE. 2007;2:e753.
18. Seto D, West DJ, Loli VA. Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. Pediatr Infect Dis J. 2002;21:793-795.
19. Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J. 2003;22:157-163.
20. Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunization in four Pacific Island countries. Vaccine. 2004;22:2791-2799.
21. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004;23:650-655.
22. Boxall E H, Sira J A, El-Shuhkri N, Kelly DA. Longterm persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis. 2004;190:1264-1269.
23. Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis. 2008;197:1419-1426.
24. Bialek SR, Bower WA, Novak R, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J. 2008;27:881-885.
25. Hollinger FB, Adam E, Heiberg D, Melnick JL. Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard JE, (eds). Viral Hepatitis-1981 International Symposium. Philadelphia: The Franklin Institute Press, 1982:451-466.
26. AlFaleh F, AlShehri S, AlAnsari S, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008;57:404-409.
27. Jarrosson L, Kolopp-Sarda MN, Aguilar P, et al. Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses. Vaccine 2004;22:3789-3796.
28. Bulkow LR, Wainwright RB, McMahon BJ, Parkinson AJ. Increases in levels of antibody to hepatitis B surface antigen in an immunized population. Clin Infect Dis. 1998;26:933-937.
29. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200:1390-1396.
30. Tichmann I, Grunert D, Habash S, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccines and evaluation of booster vaccination. Hum Vaccin. 2006;2:249-254.
31. Giambi C, Bella A, Barale A, et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis. 2008;8:100.
32. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366:1379-1384.
33. Zinke M, Kappes R, Kindler K, et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin 2009;5:592-598.